A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.

Autor:	Bezinelli LM; Hospital Israelita Albert Einstein., Eduardo FP; Hospital Israelita Albert Einstein., Migliorati CA; University of Florida College of Dentistry, Gainesville, FL., Ferreira MH; Hospital Israelita Albert Einstein., Taranto P; Oncology Division., Sales DB; Oncology Division., Santi CG; Department of Dermatology., Macarenco RS; Department of Anatomic Pathology, Hospital Israelita Albert Einstein., Godoy CPV; Oncology Division., Corrêa L; Department of General Pathology, School of Dentistry, University of São Paulo., Buzaid AC; Oncology Division.; Oncology Division, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2019 Nov/Dec; Vol. 42 (9), pp. 359-362.
DOI:	10.1097/CJI.0000000000000280
Abstrakt:	Pembrolizumab is a humanized antibody that targets the programmed death-1 receptor expressed in T cells with high selectivity. This therapeutic is of great importance in cancer immunotherapy yet managing the potential immune-related adverse events remains a concern. Here, we report a rare case of mucous membrane pemphigoid in the oral mucosa, upper respiratory tract, and conjunctiva of a patient with ovarian adenocarcinoma without cutaneous manifestation, which persisted even after pembrolizumab discontinuation. A brief review of pembrolizumab-related bullous pemphigoid cases is presented and possible mechanisms underlying these lesions are discussed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu